ZA924007B - Crystalline oxathiolane derivatives - Google Patents

Crystalline oxathiolane derivatives

Info

Publication number: ZA924007B
Authority: ZA; South Africa
Prior art keywords: oxathiolane derivatives; crystalline; crystalline oxathiolane; derivatives; oxathiolane
Prior art date: 1991-06-03

Application number

ZA924007A

Other languages

English (en)

Inventor

Paul Ravenscroft

Tony Gordon Roberts

Paul Evans

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-06-03

Filing date

1992-06-02

Publication date

1993-04-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10696001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA924007(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-06-02 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

1993-04-28 Publication of ZA924007B publication Critical patent/ZA924007B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Secondary Cells (AREA)

ZA924007A 1991-06-03 1992-06-02 Crystalline oxathiolane derivatives ZA924007B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB919111902A GB9111902D0 (en)	1991-06-03	1991-06-03	Chemical compounds

Publications (1)

Publication Number	Publication Date
ZA924007B true ZA924007B (en)	1993-04-28

Family

ID=10696001

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA924007A ZA924007B (en)	1991-06-03	1992-06-02	Crystalline oxathiolane derivatives

Country Status (30)

Country	Link
US (1)	US5905082A (is)
EP (2)	EP0517145B1 (is)
JP (1)	JP2851480B2 (is)
KR (1)	KR100244008B1 (is)
AP (1)	AP300A (is)
AT (1)	ATE212630T1 (is)
AU (2)	AU1881092A (is)
BG (1)	BG60914B1 (is)
CA (2)	CA2311988C (is)
CZ (1)	CZ284513B6 (is)
DE (1)	DE69232387T2 (is)
DK (1)	DK0517145T3 (is)
ES (1)	ES2171158T3 (is)
GB (1)	GB9111902D0 (is)
GE (1)	GEP19991834B (is)
IE (2)	IE20020782A1 (is)
IL (1)	IL102073A (is)
IS (2)	IS1867B (is)
MX (1)	MX9202619A (is)
NO (1)	NO301713B1 (is)
NZ (1)	NZ242981A (is)
OA (1)	OA09913A (is)
PT (1)	PT517145E (is)
RU (1)	RU2102393C1 (is)
SG (1)	SG52455A1 (is)
SK (1)	SK281249B6 (is)
TW (1)	TW254939B (is)
UA (1)	UA41265C2 (is)
WO (1)	WO1992021676A1 (is)
ZA (1)	ZA924007B (is)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4581979A (en) *	1983-07-01	1986-04-15	Automotive Products Plc	Shipping and installation restraining clip for master cylinder input member
US5728575A (en) *	1990-02-01	1998-03-17	Emory University	Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) *	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) *	1990-02-01	1994-01-04	Emory University	Method of synthesis of 1,3-dioxolane nucleosides
US6642245B1 (en)	1990-02-01	2003-11-04	Emory University	Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5444063A (en) *	1990-12-05	1995-08-22	Emory University	Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6812233B1 (en)	1991-03-06	2004-11-02	Emory University	Therapeutic nucleosides
US5817667A (en) *	1991-04-17	1998-10-06	University Of Georgia Research Foudation	Compounds and methods for the treatment of cancer
GB9116601D0 (en) *	1991-08-01	1991-09-18	Iaf Biochem Int	1,3-oxathiolane nucleoside analogues
US6177435B1 (en)	1992-05-13	2001-01-23	Glaxo Wellcome Inc.	Therapeutic combinations
US20020120130A1 (en)	1993-09-10	2002-08-29	Gilles Gosselin	2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) *	1994-01-28	1996-12-24	Univ. Of Ga Research Foundation	L-nucleosides
IL115156A (en) *	1994-09-06	2000-07-16	Univ Georgia	Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en)	1995-01-27	2002-05-21	Emory University	[5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en)	1995-01-27	1997-12-30	Emory University	Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) *	1995-01-30	1998-09-15	Yale University	L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
DE69636734T2 (de)	1995-06-07	2007-10-18	Emory University	Nucleoside mit anti-hepatitis b virus wirksamkeit
US5914332A (en) *	1995-12-13	1999-06-22	Abbott Laboratories	Retroviral protease inhibiting compounds
AU727983B2 (en)	1996-06-25	2001-01-04	Glaxo Group Limited	Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatment of HIV
US5753789A (en) *	1996-07-26	1998-05-19	Yale University	Oligonucleotides containing L-nucleosides
TW536403B (en) *	1997-03-24	2003-06-11	Glaxo Group Ltd	An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
US6436948B1 (en)	2000-03-03	2002-08-20	University Of Georgia Research Foundation Inc.	Method for the treatment of psoriasis and genital warts
ATE383355T1 (de)	2001-03-01	2008-01-15	Abbott Lab	Polymorph und andere kristallinische formen von zusammen-ftc
CA2351049C (en)	2001-06-18	2007-03-13	Brantford Chemicals Inc.	Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
WO2003027106A1 (en) *	2001-09-25	2003-04-03	Cadila Healthcar Limited	Process for the preparation of crystalline polymorph ii of lamivudine
CA2477088A1 (en)	2002-02-22	2003-10-02	New River Pharmaceuticals Inc.	Active agent delivery systems and methods for protecting and administering active agents
AU2003291457A1 (en) *	2002-11-08	2004-06-03	Glaxo Group Limited	Pharmaceutical antiviral compositions
EA201100293A1 (ru) *	2003-01-14	2011-08-30	Джилид Сайэнс, Инк.	Способ (варианты) и фармацевтическая композиция (варианты) для лечения или профилактики симптомов вич-инфекции
DE602005011321D1 (de) *	2004-11-10	2009-01-08	Novartis Vaccines & Diagnostic	Deamidiertes interferon-beta
US20060242012A1 (en) *	2005-04-22	2006-10-26	Sumit Agarwal	Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest
TWI471145B (zh)	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
TWI375560B (en)	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
DE602007009957D1 (de) *	2006-04-18	2010-12-02	Lupin Ltd	Neue kristalline form von lamivudin
WO2009031026A2 (en) *	2007-09-06	2009-03-12	Combino Pharm, S.L.	Novel pharmaceutical compositions
WO2009037538A2 (en) *	2007-09-17	2009-03-26	Aurobindo Pharma Ltd	Process for the preparation of lamivudine form i
WO2009069011A1 (en) *	2007-11-29	2009-06-04	Ranbaxy Laboratories Limited	Process for the preparation of substituted 1,3-oxathiolanes
AU2008331168A1 (en) *	2007-11-29	2009-06-04	Ranbaxy Laboratories Limited	Crystalline form I of lamivudine and its preparation
AU2008331167A1 (en) *	2007-11-29	2009-06-04	Ranbaxy Laboratories Limited	Process and intermediates for the preparation of substituted 1, 3-oxathiolanes, especially lamivudine
WO2009127996A1 (en) *	2008-04-17	2009-10-22	Ranbaxy Laboratories Limited	Novel crystalline form of lamivudine
EP2318398A4 (en) *	2008-09-01	2011-12-07	Hetero Research Foundation	PROCESS FOR PREPARING A POLYMORPHIC FORM OF LAMIVUDIN
WO2010055526A1 (en) *	2008-11-12	2010-05-20	Lupin Limited	A novel polymorph of emtricitabine and a process for preparing of the same
CN101531656B (zh) *	2009-03-24	2010-12-08	福建广生堂药业有限公司	拉米夫定晶型及其制备方法
CN101993439B (zh) *	2009-03-24	2013-04-24	福建广生堂药业股份有限公司	拉米夫定晶型及其制备方法
US8481554B2 (en) *	2009-05-27	2013-07-09	Hetero Research Foundation	Solid oral dosage forms of lamivudine
WO2011007367A1 (en)	2009-07-15	2011-01-20	Lupin Limited	An improved process for preparation of efavirenz
DK2488516T3 (en)	2009-10-14	2015-05-26	Mylan Lab Ltd	Method of producing lamivudine and novel salts in the preparation thereof
SMT201800290T1 (it)	2010-01-27	2018-07-17	Viiv Healthcare Co	Terapia antivirale
WO2011095987A1 (en) *	2010-02-03	2011-08-11	Matrix Laboratories Ltd.	Novel process for the preparation of cis-nucleoside derivative
CA2789078A1 (en) *	2010-02-12	2011-08-18	Merck Sharp & Dohme Corp.	Preparation of lamivudine form i
US20130115237A1 (en)	2010-06-09	2013-05-09	Vaccine Technologies, Incorporated	Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment
WO2013021290A1 (en)	2011-08-05	2013-02-14	Lupin Limited	A stereoselective process for preparation of 1,3-oxathiolane nucleosides
WO2013168066A1 (en)	2012-05-05	2013-11-14	Lupin Limited	An improved process for the manufacture of lamivudine form i.
CN114099454B (zh) *	2020-08-31	2023-06-27	长春海悦药业股份有限公司	一种拉米夫定片及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ228645A (en) *	1988-04-11	1991-09-25	Iaf Biochem Int	1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5047407A (en) *	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) *	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) *	1990-05-02	1990-06-27	Glaxo Group Ltd	Chemical compounds
US5248776A (en) *	1990-12-05	1993-09-28	University Of Georgia Research Foundation, Inc.	Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5179104A (en) *	1990-12-05	1993-01-12	University Of Georgia Research Foundation, Inc.	Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
JPH04358486A (ja) *	1991-06-04	1992-12-11	Toshiba Corp	高能率符号化信号処理装置

1991
- 1991-06-03 GB GB919111902A patent/GB9111902D0/en active Pending
1992
- 1992-02-06 UA UA93004068A patent/UA41265C2/uk unknown
- 1992-06-02 ZA ZA924007A patent/ZA924007B/xx unknown
- 1992-06-02 DK DK92109221T patent/DK0517145T3/da active
- 1992-06-02 AU AU18810/92A patent/AU1881092A/en not_active Abandoned
- 1992-06-02 EP EP92109221A patent/EP0517145B1/en not_active Expired - Lifetime
- 1992-06-02 CA CA002311988A patent/CA2311988C/en not_active Expired - Lifetime
- 1992-06-02 JP JP4166809A patent/JP2851480B2/ja not_active Expired - Lifetime
- 1992-06-02 EP EP01200491A patent/EP1099700A1/en not_active Withdrawn
- 1992-06-02 TW TW081104300A patent/TW254939B/zh not_active IP Right Cessation
- 1992-06-02 DE DE69232387T patent/DE69232387T2/de not_active Expired - Lifetime
- 1992-06-02 AT AT92109221T patent/ATE212630T1/de active
- 1992-06-02 IL IL10207392A patent/IL102073A/en not_active IP Right Cessation
- 1992-06-02 WO PCT/EP1992/001213 patent/WO1992021676A1/en not_active Ceased
- 1992-06-02 ES ES92109221T patent/ES2171158T3/es not_active Expired - Lifetime
- 1992-06-02 SK SK1257-93A patent/SK281249B6/sk not_active IP Right Cessation
- 1992-06-02 MX MX9202619A patent/MX9202619A/es active IP Right Grant
- 1992-06-02 KR KR1019920009537A patent/KR100244008B1/ko not_active Expired - Lifetime
- 1992-06-02 RU RU93058495A patent/RU2102393C1/ru active
- 1992-06-02 AP APAP/P/1992/000395A patent/AP300A/en active
- 1992-06-02 NZ NZ242981A patent/NZ242981A/en not_active IP Right Cessation
- 1992-06-02 CA CA002070230A patent/CA2070230C/en not_active Expired - Lifetime
- 1992-06-02 AU AU17361/92A patent/AU656379B2/en not_active Expired
- 1992-06-02 PT PT92109221T patent/PT517145E/pt unknown
- 1992-06-02 SG SG1996004763A patent/SG52455A1/en unknown
- 1992-06-02 US US07/892,029 patent/US5905082A/en not_active Expired - Lifetime
- 1992-06-02 CZ CS932612A patent/CZ284513B6/cs not_active IP Right Cessation
- 1992-06-02 NO NO922182A patent/NO301713B1/no not_active IP Right Cessation
- 1992-06-02 IS IS3873A patent/IS1867B/is unknown
- 1992-06-02 GE GEAP19922654A patent/GEP19991834B/en unknown
- 1992-07-01 IE IE20020782A patent/IE20020782A1/en not_active IP Right Cessation
- 1992-07-01 IE IE178092A patent/IE921780A1/en not_active IP Right Cessation
- 1992-12-04 IS IS4268A patent/IS4268A/is unknown
1993
- 1993-11-15 OA OA60437A patent/OA09913A/en unknown
- 1993-11-30 BG BG98254A patent/BG60914B1/bg unknown

Also Published As

Publication number	Publication date
NO922182D0 (no)	1992-06-02
KR930000511A (ko)	1993-01-15
SG52455A1 (en)	1998-09-28
IS1867B (is)	2003-05-02
HK1009599A1 (en)	1999-06-04
AU1736192A (en)	1993-03-11
CA2311988A1 (en)	1992-12-04
WO1992021676A1 (en)	1992-12-10
CA2070230A1 (en)	1992-12-04
EP1099700A1 (en)	2001-05-16
DE69232387D1 (de)	2002-03-14
IE921780A1 (en)	1992-12-16
EP0517145B1 (en)	2002-01-30
US5905082A (en)	1999-05-18
PT517145E (pt)	2002-07-31
CA2311988C (en)	2005-11-15
SK125793A3 (en)	1994-11-09
CA2070230C (en)	2004-08-03
OA09913A (en)	1994-09-15
JPH06211848A (ja)	1994-08-02
AU1881092A (en)	1993-01-08
IS3873A (is)	1992-12-04
SK281249B6 (sk)	2001-01-18
AU656379B2 (en)	1995-02-02
DK0517145T3 (da)	2002-05-06
DE69232387T2 (de)	2002-09-26
GB9111902D0 (en)	1991-07-24
NO922182L (no)	1992-12-04
GEP19991834B (en)	1999-11-05
NO301713B1 (no)	1997-12-01
IL102073A (en)	1996-05-14
IE20020782A1 (en)	2003-04-02
IS4268A (is)	1995-02-27
NZ242981A (en)	1994-04-27
CZ284513B6 (cs)	1998-12-16
MX9202619A (es)	1992-12-01
ES2171158T3 (es)	2002-09-01
EP0517145A1 (en)	1992-12-09
IL102073A0 (en)	1993-01-14
RU2102393C1 (ru)	1998-01-20
JP2851480B2 (ja)	1999-01-27
UA41265C2 (uk)	2001-09-17
KR100244008B1 (ko)	2000-03-02
AP300A (en)	1994-01-20
AP9200395A0 (en)	1992-07-31
ATE212630T1 (de)	2002-02-15
CZ261293A3 (en)	1994-04-13
BG98254A (bg)	1994-07-29
BG60914B1 (bg)	1996-06-28
TW254939B (is)	1995-08-21

Publication	Publication Date	Title
SG52455A1 (en)	1998-09-28	Crystalline oxathiolane derivatives
GR3023621T3 (en)	1997-08-29	3-Hydroxy-4-aryl-5-oxo-pyrazolin derivatives
HU9201430D0 (en)	1992-07-28	Phosphono/biaril-dipeptide derivatives
HU9203994D0 (en)	1993-04-28	Imidazo-pyridine derivatives
GB9100505D0 (en)	1991-02-20	Piperidine derivatives
HU9202768D0 (en)	1992-12-28	Cyano-phenyl-pyrrole derivatives
EP0438690A3 (en)	1992-05-27	Substituted pyrazolin derivatives
HU9303225D0 (en)	1994-03-28	Benzofurane derivatives
ZA92278B (en)	1992-10-28	3-quinuclidine derivatives
HU9202388D0 (en)	1992-10-28	Aryl-alkyl-amine derivatives
ZA922976B (en)	1993-10-25	4-Aryl-3-heteroarylureidoquinoline derivatives
EP0520435A3 (en)	1993-05-05	Dc-89 derivatives
IL96048A0 (en)	1991-07-18	Crystalline polyimidesiloxanes
GB2262739B (en)	1995-05-17	Benzofuranylimidazole derivatives
HU9200011D0 (en)	1992-03-30	Trifluoro-methyl-1-carba(1-dethia)-cepheme derivatives
GB9102423D0 (en)	1991-03-20	Pryimidinyl-and triazinylsalicyl-and-picolinylaldehyde derivatives
HU9200105D0 (en)	1992-04-28	Bipiridyl derivatives
GB9118543D0 (en)	1991-10-16	Novel crystalline intermediate
GB9213972D0 (en)	1992-08-12	3-cycloalkyl-prop-2-enamide derivatives
ZA924959B (en)	1993-03-31	Hydroisoquinoline derivatives
GB9106073D0 (en)	1991-05-08	Benzodioxanylimidazoline derivatives
GB9111709D0 (en)	1991-07-24	Imidazopiperidine derivatives
GB9111684D0 (en)	1991-07-24	Imidazopiperidine derivatives
GB9110611D0 (en)	1991-07-03	Pyrrolo-pyriding derivatives
GB9106070D0 (en)	1991-05-08	Benzodioxanylimidazole derivatives